Drugs / Atosiban
last change Dec 2025 re-read 2 minutes ago

Atosiban

Other / unclassified targets OXTR via inhibition

Developed for
female infertility · endometriosis · infertility disorder · pregnancy loss, recurrent, 4 · low implantation of placenta · pregnancy disorder
Investigated by
Radboud University Medical Center · University of Electronic Science and Technology of China · Academic Medical Center - University of Amsterdam · Amphia Hospital · An Sinh Hospital · Bezmialem Vakif University
+38 more · Children's Hospital of Chongqing Medical University · Deventer Ziekenhuis · Diakonessenhuis, Utrecht · Erasmus Medical Center · Ferring Pharmaceuticals · First Affiliated Hospital of Chongqing Medical University · Flevoziekenhuis · Franciscus Gasthuis · Frisius Medisch Centrum · Gelre Hospitals · Groene Hart Ziekenhuis · Haaglanden Medical Centre · Isala · Leiden University Medical Center · Maastricht University Medical Center · Martini Hospital Groningen · Maxima Medical Center · Medisch Spectrum Twente · National Maternity Hospital, Ireland · Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Nottingham University Hospitals NHS Trust · OLVG · Polish Mother Memorial Hospital Research Institute · Raed Salim · Rijnstate Hospital · Shanghai First Maternity and Infant Hospital · Spaarne Gasthuis · St. Antonius Hospital · Tel-Aviv Sourasky Medical Center · Tergooi Hospital · UMC Utrecht · University Hospital, Ghent · University Medical Center Groningen · Vietnam National University · Yeditepe University · Ziekenhuisgroep Twente · ZonMw: The Netherlands Organisation for Health Research and Development · Zuyderland Medical Centre

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Tractocile 2000-01-20 europa.eu

Trials 14 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT07140237 Sep → Dec 2025 overdue University of Electronic Science and Technology of China Recruiting No outcome recorded
Phase 0 NCT07093060 Jun → Nov 2025 overdue University of Electronic Science and Technology of China Recruiting No outcome recorded
Phase 12 trials
Phase 1 NCT02893722 Jan 2017 → Jan 2018 pregnancy loss, recurrent, 4 Shanghai First Maternity and Infant Hospital Unknown No outcome recorded
Phase 1 NCT00679705 May → Nov 2008 University Hospital, Ghent Completed No outcome recorded
Phase 22 trials
Phase 2 NCT05382143 Feb → Jun 2022 endometriosis Radboud University Medical Center Unknown No outcome recorded
Phase 2 NCT00587327 Nov 2007 → May 2008 Ferring Pharmaceuticals Completed No outcome recorded
Phase 31 trial
Phase 3 NCT02725736 Mar 2016 → Mar 2018 Tel-Aviv Sourasky Medical Center Unknown No outcome recorded
Phase 42 trials
Phase 4 NCT05693688 Dec 2017 → Feb 2024 Academic Medical Center - University of Amsterdam Completed No outcome recorded
Phase 4 NCT00599898 Jan 2008 → Dec 2011 Raed Salim Completed No outcome recorded
Phase not applicable5 trials
NCT07185230 Dec 2025 → Jun 2027 expected female infertility Northwest Women's and Children's Hospital, Xi'an, Shaanxi Recruiting No outcome recorded
NCT03904745 Dec 2020 → Jul 2021 female infertility Bezmialem Vakif University Unknown No outcome recorded
NCT06537778 Jan 2018 → Feb 2024 cervix disorder Children's Hospital of Chongqing Medical University Completed No outcome recorded
NCT03570294 Feb 2014 → Jun 2018 Polish Mother Memorial Hospital Research Institute Completed No outcome recorded
NCT01493440 Mar → Aug 2011 infertility disorder An Sinh Hospital Completed No outcome recorded
Also used as a comparator or background therapy in 7 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT03369262 Background Jan 2018 → Jul 2020 ObsEva SA Unknown No outcome recorded
Phase 2 NCT01429545 Comparator Apr 2007 → Sep 2010 Tawam Hospital Completed No outcome recorded
Phase 33 trials
Phase 3 NCT02292784 Comparator Jun 2015 → Sep 2019 pregnancy disorder GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT02292771 Comparator Mar 2015 → Aug 2017 pregnancy disorder GlaxoSmithKline Terminated No outcome recorded
Phase 3 NCT01314859 Comparator Jul 2011 → Jul 2012 Hospital Clinico Universitario de Santiago Withdrawn No outcome recorded
Phase 42 trials
Phase 4 NCT01673399 Comparator Feb 2012 → Feb 2015 low implantation of placenta AZ Jan Palfijn Gent Completed No outcome recorded
Phase 4 NCT01501214 Comparator Dec 2011 → Dec 2013 female infertility The University of Hong Kong Completed No outcome recorded

Evidence & citations 20 cited values

Every value below carries the sentence it was read from. 22 sources stand behind the page.

FieldValueCited text
Known as Atosiban ClinicalTrials.gov intervention name — accepted as the source's own label NCT00587327
20

NCT02893722

NCT07140237

NCT02292771

NCT02292784

NCT03904745

NCT02725736

NCT01429545

NCT03570294

NCT01314859

NCT01673399

NCT00599898

NCT03369262

NCT05382143

NCT07093060

NCT01493440

NCT00679705

NCT05693688

NCT01501214

NCT06537778

NCT07185230

Known as Antocile ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as Antocin ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as Antocin ii ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as Atosiban (as acetate) ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as ATOSIBAN ACETATE ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as Atosiban sun ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as CAP-449 ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as CAP-476 ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as CAP-581 ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as F-314 ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as ORF 22164 ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as RW-22164 ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as RWJ 22164 ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as Tractocil ChEMBL registry synonym — accepted as the source's own label CHEMBL382301
Known as Tractocile “Participants allocated to the Atosiban group will be administered Atosiban (37.5 mg/5 mL, Tractocile®, Ferring Pharma, Geneva, Switzerland)” NCT07185230
1

“Atosiban (Tractocile), maximum 300 µg/minute, IV” NCT00679705

Action Inhibit “mixed oxytocin antagonist - vasopressin V1a antagonist (atosiban)” NCT00587327
1

“Oxytocin receptor antagonist” CHEMBL382301

Modality Other / unclassified “atosiban (oxytocin antagonist)” NCT01429545
Route Intravenous “Solution for IV administration.” NCT00587327
Target OXTR “Oxytocin receptor antagonist” CHEMBL382301